Recent Updates
Recently added Catalysts

EVRA contraceptive patch containing of norelgestromin and of ethinyl estradiol

Phase 1

Contraception | Small molecule | Endocrine |Johnson & Johnson|Trials Updated: Jun 8, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedUNCONTROLLED
Total Trials2
Total Enrollment94

FDA Designations

No designations recorded

EVRA contraceptive patch containing of norelgestromin and of ethinyl estradiol clinical trials

EVRA contraceptive patch containing of norelgestromin and of ethinyl estradiol · 2 trials · 2 indications

Phase 1 2
NCT00258063A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)Contraception
COMPLETED60 Analytics
NCT00254865A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female VolunteersContraception
COMPLETED34 Analytics
PHASE1COMPLETED
A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)
Contraception
NCT0025806360
Unlock trial analytics
PHASE1COMPLETED
A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
Contraception
NCT0025486534
Unlock trial analytics

Study Endpoints

Primary Endpoints

A comparison of exposure and pharmacokinetics for norelgestromin, (NGMN), norgestrel (NG), and ethinyl estradiol (EE) for EVRA®, CILEST® and historical data from one ORTHO EVRA® clinical development lot.
A comparison of the total exposure and pharmacokinetics, over comparable time intervals (Week 1 of Cycle 1 and Week 3 of Cycle 2), of NGMN, NG, and EE for ORTHO EVRA® and CILEST®.

Secondary Endpoints

An assessment of safety from screening to final visit (incidence of adverse events, changes in physical, gynecologic and breast examinations, vital signs, laboratory tests and electrocardiogram results).
Pharmacodynamic measurements [sex hormone-binding globulin (SHBG), corticosteroid binding globulin (CBG), and corticosteroid-binding globulin binding capacity (CBG-BC)] during pre-treatment, Cycle 1, Washout and Cycle 2.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Interventions

NameTypeDescription
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).DRUG -
EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexFEMALE
Healthy VolunteersYes

Inclusion Criteria: * Subjects who are not pregnant (as demonstrated by negative pregnancy tests at screening and before admission for each treatment period) and who have completed their last term pregnancy at least 60 days before the admission visit * confirmed to be in good health as determined b...

Unlock Eligibility Criteria

Frequently asked questions about EVRA contraceptive patch containing of norelgestromin and of ethinyl estradiol

What is EVRA contraceptive patch used for?

EVRA is a transdermal contraceptive patch used for contraception in women. It delivers norelgestromin and ethinyl estradiol through the skin. The patch is a small molecule combination hormonal contraceptive developed by Johnson & Johnson (ticker: JNJ).

Who makes EVRA contraceptive patch?

EVRA is made by Johnson & Johnson, which trades under the ticker JNJ. The patch is a transdermal contraceptive containing norelgestromin and ethinyl estradiol. It is a small molecule product in the endocrine therapeutic area.

What phase is EVRA contraceptive patch in?

EVRA contraceptive patch is in Phase 1 clinical development. Two Phase 1 trials have been completed, with no active trials ongoing. The trials enrolled a total of 94 healthy female volunteers aged 18 years and older.

What clinical trials is EVRA contraceptive patch in?

EVRA contraceptive patch has been studied in two completed Phase 1 trials: NCT00258063, which evaluated exposure from commercial lots of EVRA and CILEST in 60 volunteers, and NCT00254865, a comparative pharmacokinetic study of ORTHO EVRA and CILEST in 34 healthy female volunteers.

Is EVRA contraceptive patch the same as CILEST?

No, EVRA contraceptive patch and CILEST are different products. EVRA is a transdermal patch containing norelgestromin and ethinyl estradiol, while CILEST is an oral contraceptive tablet. The two were compared in Phase 1 pharmacokinetic trials.

What does EVRA contraceptive patch contain?

EVRA contraceptive patch contains norelgestromin and ethinyl estradiol. The patch is a small molecule transdermal contraceptive developed by Johnson & Johnson (ticker: JNJ) for contraception in women.

Explore more on BiopharmaWatch

Johnson & Johnson (JNJ)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track